Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Osteoporosis
Interventions: Hormone replacement therapy, Strength training; Drug · Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Menopause
Interventions: Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate; Drug
Lead sponsor: Jeanne Drisko, MD, CNS, FACN; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Osteoarthritis
Interventions: Not listed
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Health Promotion, Cardiovascular Health
Interventions: Health Impact 360, Usual care - Wait list control; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Detroit, Michigan • Flint, Michigan

Conditions: Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1; Other · Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more

Conditions: Alzheimer's Disease
Interventions: MRI, MR Spectroscopy, MR Perfusion; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 45 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Diseases, Metabolism, Inborn Errors
Interventions: SCH-58235, Ezetimibe; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Kidney Disease
Interventions: PRT-201, Placebo; Drug
Lead sponsor: Proteon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 18 more

Conditions: Cardiovascular Disease, Cigarette Smoking
Interventions: Subject's usual brand (UB) tobacco product; Other
Lead sponsor: R.J. Reynolds Tobacco Company; Industry
Eligibility: 26 Years to 49 Years · Male only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hyperlipidemia
Interventions: LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Madison, Wisconsin

Conditions: Cholesterol, Elevated, Elevated Cholesterol
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Hypertriglyceridemia
Interventions: Maraviroc, placebo; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dyslipidemias
Interventions: Niacin, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Breast Tumors, Cancer of Breast
Interventions: Metformin, Atorvastatin, Breast surgery; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Degeneration
Interventions: Celecoxib (Celebrex); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabete Type 2, Obesity & Overweight, Nutritional Intervention, Food Insecurity
Interventions: Meal kits, No-prep meals, Culinary nutrition classes, Text messages; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Cholesterol, Elevated, Diabetes Mellitus
Interventions: Guided management, Self management; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 39 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: PF-04950615 (RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 9
States / cities: Culver City, California • Glendale, California • Miami, Florida + 4 more

Conditions: Alzheimer Disease
Interventions: Atorvastatin calcium; Drug
Lead sponsor: Institute for the Study of Aging (ISOA); Other
Eligibility: 50 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Sun City, Arizona

Conditions: Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions: AlmegaPL (FDA NDIN # 826); Dietary Supplement
Lead sponsor: Qualitas Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Houston, Texas

Conditions: Physicians' Practice Patterns, Coronary Heart Disease
Interventions: education and reminder; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 11,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Bone Estrogen Strength Training

Bioidentical 'Natural' Hormone Evaluation in Early Menopause

Anti-inflammatory Agents and Cholesterol Metabolism

Health Impact 360: Advancing Physical, Social, and Mental Health Toward Cardiovascular Disease Prevention in Community Settings

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study

Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

A Pilot Study to Explore the Role of Gut Flora in Elevated Cholesterol

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Laser and Medical Treatment of Diabetic Macular Edema

Mutations Associated With Parkinson s Disease

Nutrition Intervention Optimization to Better Utilize Resources and Support Health

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Community Intervention to Improve CVD Risk Factor Control in Young American Indians

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Lipitor as a Treatment for Alzheimer's Disease

AlmegaPL CV Health Open Label Study

From Research to Practice - Lipid Management for Low HDL-Cholesterol